S&P 500 7,736 +4.14% Nasdaq 26,550 +6.73% Dow Jones 54,170 +2.70% FTSE 100 10,879 +0.08% DAX 26,202 +2.90% Nikkei 225 63,958 +4.11% Hang Seng 25,853 +2.14% WTI Crude 75.65 -9.50% Gold 4,158 +1.41% US 10-Year Treasury Yield 4.627 +0.11% S&P 500 7,736 +4.14% Nasdaq 26,550 +6.73% Dow Jones 54,170 +2.70% FTSE 100 10,879 +0.08% DAX 26,202 +2.90% Nikkei 225 63,958 +4.11% Hang Seng 25,853 +2.14% WTI Crude 75.65 -9.50% Gold 4,158 +1.41% US 10-Year Treasury Yield 4.627 +0.11%

LATEST

Palantir climbs 27% on 'otherworldly' AI demand; Karp tells shareholders business has 'Marxist' values●Senators seek SEC probe of President Trump’s memecoin as crypto bill enters into a pivotal week●How war in Myanmar is driving a deadly rare earth mining boom●Putin signs law bringing Russia's crypto market under central bank licensing●The richest 20% are buying most of the new cars sold in the U.S.●Republicans Continue To Blame Democrats Over Stalled Crypto Clarity Act●Hormuz supply disruption reshapes economics for Dune Oil's Turkish oil block●Fidji Simo had to leave OpenAI. But she's still building a business that could find cures to chronic diseases that affect women like her●Palantir climbs 27% on 'otherworldly' AI demand; Karp tells shareholders business has 'Marxist' values●Senators seek SEC probe of President Trump’s memecoin as crypto bill enters into a pivotal week●How war in Myanmar is driving a deadly rare earth mining boom●Putin signs law bringing Russia's crypto market under central bank licensing●The richest 20% are buying most of the new cars sold in the U.S.●Republicans Continue To Blame Democrats Over Stalled Crypto Clarity Act●Hormuz supply disruption reshapes economics for Dune Oil's Turkish oil block●Fidji Simo had to leave OpenAI. But she's still building a business that could find cures to chronic diseases that affect women like her●

Asia

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Markets-Economic Times · 1h ago · 🇮🇳 India

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, actively pushing its obesity treatment initiatives.

Read the full story at Markets-Economic Times →

More Asia

Palantir climbs 27% on 'otherworldly' AI demand; Karp tells shareholders business has 'Marxist' values

mint - markets · 23m ago

US Fed's Anna Paulson keeps 'open mind' on rate decisioin as inflation remains too high

Markets-Economic Times · 36m ago

Yen eases but retains intervention-driven gains

Latest News · 1h ago

Palantir stock jumps 27% after ‘otherworldly’ demand lifts outlook

Markets-Economic Times · 1h ago